Recombinant Bivalent(GI.1/GII.4) norovirus vaccine (National Vaccine and Serum Institute)

To evaluate the immunogenicity of different doses of recombinant norovirus bivalent (GI.1/GII.4) vaccine (Hansen yeast) in healthy people aged 6 months to 59 years 14 days after full immunization. To further evaluate the safety of different doses of the experimental vaccine in healthy people aged 6 months to 59 years; to explore the immune persistence of the experimental vaccine in healthy people aged 6 months to 59 years.

To evaluate the tolerability and safety of recombinant norovirus bivalent (GI.1/GII.4) vaccine (Hansen's yeast) in healthy people aged 6 months to 59 years; to preliminarily explore the immunogenicity of recombinant norovirus bivalent (GI.1/GII.4) vaccine (Hansen's yeast) in healthy people aged 6 months to 59 years and the immunization schedule for the 6-35 month age group.